Taxotere docetaxel: Phase III data; marketed to treat locally advanced or metastatic breast cancer after failure of prior chemotherapy

In a 429-patient Phase III trial, time to disease progression was 37 weeks for patients treated with docetaxel plus doxorubicin compared to 32 weeks for doxorubicin plus cyclophosphamide. Overall resp...